“Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial”
14 May 2021
New QLG paper accepted by the journal “The Lancet Oncology”:
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Background
The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improved recurrence-free survival (hazard ratio [HR] 0·57 [98·4% CI 0·43–0·74], p<0·0001) compared with placebo, leading to its approval in the USA and Europe. This report provides the final results for the secondary efficacy endpoint, distant metastasis-free survival and an update of the recurrence-free survival results.
Related News
New study validates clustering of QLQ-30 HRQoL scales, which can help symptom burden management and inform clinical trial design
27 May 2022
EORTC QLG Executive Committee – Call for Candidates
18 Mar 2022
EORTC Quality of Life Group Open Access Policy
15 Mar 2022
New QLG publication “Developing an e-learning course on the use of PRO measures in oncological practice: health care professionals’ preferences for learning content and methods”
24 Nov 2021
“Psychometric validation of the European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22)”
28 Jul 2021
“Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors”
17 May 2021
“Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients”
22 Oct 2020
“Minimally important differences for interpreting the EORTC QLQ-C30 in advanced colorectal cancer patients treated with chemotherapy”
13 Aug 2020
UPDATE – 17-18 September 2020 Quality of Life Group Virtual Autumn meeting
9 Jun 2020